Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Down 2.5% - Here's Why

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares were down 2.5% on Friday . The company traded as low as $96.81 and last traded at $97.25. Approximately 2,221 shares were traded during mid-day trading, an increase of 63% from the average daily volume of 1,360 shares. The stock had previously closed at $99.70.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an "overweight" rating for the company.

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The company has a 50 day simple moving average of $108.12 and a 200-day simple moving average of $119.71. The stock has a market capitalization of $5.01 billion, a P/E ratio of -40.02 and a beta of 0.89.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.